Folotyn
Total Payments
$1.8M
Transactions
3,312
Doctors
1,417
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $286,360 | 612 | 192 |
| 2019 | $204,086 | 647 | 452 |
| 2018 | $742,451 | 1,101 | 686 |
| 2017 | $557,060 | 952 | 589 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 114 | 86.4% |
| Consulting Fee | $92,746 | 52 | 5.2% |
| Food and Beverage | $56,720 | 2,651 | 3.2% |
| Grant | $30,450 | 2 | 1.7% |
| Education | $18,807 | 429 | 1.1% |
| Space rental or facility fees (teaching hospital only) | $17,000 | 7 | 0.9% |
| Travel and Lodging | $15,533 | 52 | 0.9% |
| Honoraria | $7,400 | 3 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,100 | 2 | 0.2% |
Payments by Type
Research
$1.5M
114 transactions
General
$242,756
3,198 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| SPI-FOL-101 | Spectrum Pharmaceuticals Inc. | $694,491 | 0 |
| SPI-FOL-14-201 | Spectrum Pharmaceuticals Inc. | $314,736 | 0 |
| SPI-FOL-101 | Aurobindo Pharma USA, Inc. | $241,590 | 3 |
| FOL-14-201 | Spectrum Pharmaceuticals Inc. | $165,623 | 0 |
| Propel 008 | Spectrum Pharmaceuticals Inc. | $36,154 | 0 |
| IIS Study of Marqibo at University of Texas | Aurobindo Pharma USA, Inc. | $21,862 | 0 |
| Phase IIIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies and Multiple Myeloma | Spectrum Pharmaceuticals Inc. | $20,854 | 0 |
| SPI-FOL-14-201 | Aurobindo Pharma USA, Inc. | $17,228 | 1 |
| SPI-FOL-14-202 | Spectrum Pharmaceuticals Inc. | $14,714 | 0 |
| IIS-Zev-011 | Aurobindo Pharma USA, Inc. | $6,000 | 0 |
| SPI-FOL-14 201 SPI-FOL-101 | Aurobindo Pharma USA, Inc. | $4,624 | 1 |
| PDX-ROMI-AAAJ5656 | Spectrum Pharmaceuticals Inc. | $3,820 | 0 |
| SPI-GCF-301 | Spectrum Pharmaceuticals Inc. | $3,803 | 0 |
| SPI-EOQ-13-305 | Spectrum Pharmaceuticals Inc. | $1,050 | 1 |
| SPI-GCF-302 | Spectrum Pharmaceuticals Inc. | $652.60 | 0 |
Top Doctors Receiving Payments for Folotyn
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $1.3M | 125 |
| , MD | Hematology & Oncology | Seattle, WA | $116,308 | 8 |
| , M.D | Hematology & Oncology | Houston, TX | $114,975 | 4 |
| , MD | Hematology & Oncology | Wichita, KS | $17,262 | 5 |
| , M.D | Hematology | Rochester, MN | $16,803 | 2 |
| , MD | Medical Oncology | Charlotte, NC | $13,102 | 18 |
| , MD | Medical Oncology | New Haven, CT | $12,051 | 14 |
| , M.D, PH. D | Medical Oncology | Bronx, NY | $8,381 | 25 |
| , MD | Hematology & Oncology | Los Angeles, CA | $8,341 | 15 |
| , M.D | Hematology & Oncology | Santa Monica, CA | $6,927 | 6 |
| , D.O | Internal Medicine | Omaha, NE | $5,922 | 9 |
| , M.D | Medical Oncology | Durham, NC | $5,400 | 1 |
| , M.D | Hematology & Oncology | Houston, TX | $4,682 | 4 |
| Amitkumar Mehta | Hematology & Oncology | Birmingham, AL | $4,541 | 11 |
| , MD | Hematology & Oncology | San Diego, CA | $4,122 | 11 |
| , MD | Hematology & Oncology | Shreveport, LA | $3,871 | 3 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $3,689 | 14 |
| , MD | Internal Medicine | Charlotte, NC | $3,688 | 5 |
| , M.D | Hematology & Oncology | Charlotte, NC | $3,684 | 7 |
| , MD | Hematology | Atlanta, GA | $3,614 | 2 |
| , MD, MPH | Hospitalist | Nashville, TN | $3,320 | 3 |
| , M.D | Hematology & Oncology | Gettysburg, PA | $3,184 | 4 |
| , MD | Hematology & Oncology | Flint, MI | $3,135 | 3 |
| , M.D | Hematology & Oncology | Tucson, AZ | $2,948 | 3 |
| , MD | Hematology | Evanston, IL | $2,911 | 4 |
Ad
Manufacturing Companies
- Spectrum Pharmaceuticals Inc. $1.4M
- Aurobindo Pharma USA, Inc. $379,973
Product Information
- Type Drug
- Total Payments $1.8M
- Total Doctors 1,417
- Transactions 3,312
About Folotyn
Folotyn is a drug associated with $1.8M in payments to 1,417 healthcare providers, recorded across 3,312 transactions in the CMS Open Payments database. The primary manufacturer is Spectrum Pharmaceuticals Inc..
Payment data is available from 2017 to 2020. In 2020, $286,360 was paid across 612 transactions to 192 doctors.
The most common payment nature for Folotyn is "Unspecified" ($1.5M, 86.4% of total).
Folotyn is associated with 15 research studies, including "SPI-FOL-101" ($694,491).